(Nasdaq: DRRX) announced today that Dr.
Chief Medical Officer and Executive Vice President, Corporate Strategy.
“Dr. Stauffer’s successful leadership of clinical research and medical
affairs for pain products while at Alpharma and Abbott, and first-hand
experience with the regulatory approval process gained during his tenure at
pipeline of acute, chronic, neuropathic and post-surgical pain products,”
looking forward to the impact he will have on the development of POSIDUR(TM),
TRANSDUR(TM)-Sufentanil, ELADUR(TM) and other programs.”
Dr. Stauffer was at
position prior to the acquisition of Alpharma by
Chief Medical Officer and Senior Vice President of
pharmacology, clinical development, pharmacovigilance, medical affairs, risk
management and health outcomes/pharmacoeconomics. Prior to joining Alpharma,
Dr. Stauffer was employed at
Medical Director for
Phase I-III trials for Vicodin, Vicoprofen, Dilaudid, as well as novel
compounds targeting neuropathic pain. Prior to Abbott, he worked at the FDA
from 2000 to 2002 as a Medical Review Officer in the Analgesic Division of the
Investigational New Drug (IND) Applications and New Drug Applications (NDAs)
for opiate, non-opiate, anti-inflammatory, and novel pain compounds.
Dr. Stauffer is a founding member of the Initiative on Methods,
Measurement and Pain Assessment in Clinical Trials (IMMPACT). This on-going
collaboration between pharma, FDA, NIH, academia and patient advocacy groups
helps to develop core domains and outcomes for chronic pain clinical trials.
Dr. Stauffer graduated from the
and completed residency training in Anesthesiology at the
a veteran of the U.S. Navy, honorably discharged as a Lieutenant Commander
after serving eight years as a Naval Medical Officer. He will complete his
joint degree granted by
“I should also note that Dr.
Medical Officer, has resigned from
innovative drugs for pain and other chronic diseases, with late-stage
development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and
injectable depot delivery technologies may enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved convenience,
compliance, efficacy and safety for small molecule and biologic drugs. For
more information, please visit www.www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
PRN Photo Desk, email@example.com
Web Site: http://www.www.durect.com